



Universität Hamburg
DER FORSCHUNG | DER LEHRE | DER BILDUNG

FAKULTÄT
FÜR MATHEMATIK, INFORMATIK
UND NATURWISSENSCHAFTEN

Prof. Dr. S. Wicha · UHH · Institute of Pharmacy
Bundesstr. 45 · 20146 Hamburg · Germany

Dr Henning Gädeke,
Chair of the Global Health EDCTP3 Joint Undertaking
Governing Board
c/o Dr Michael Makanga, the Global Health EDCTP3
Joint Undertaking Executive Director
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d'Or
1060 Brussels
Belgium

Prof. Dr. Sebastian G. Wicha

Division of Mathematics, Informatics
and Natural Sciences
Institute of Pharmacy
Dept. of Clinical Pharmacy
Bundesstr. 45
20146 Hamburg
Germany

Tel. +49 40 42838-3487
Tel. +49 40 42838-3491 (Secretary)
Fax +49 40 42838-3477
sebastian.wicha@uni-hamburg.de
www.chemie.uni-hamburg.de/pha

27.09.2025

Letter of endorsement

Dear Madam or Sir,

On behalf of Dept. of Clinical Pharmacy, University of Hamburg, Germany (UHAM) and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

Universität Hamburg is the largest research and educational institution in Northern Germany and was awarded the status of a 'University of Excellence' in 2019. The research of the Clinical Pharmacy group is devoted to optimization of anti-infective therapies thereby using both experimental studies and pharmacometric modelling and simulation techniques. In particular, our expertise in pharmacology and pharmacometrics will be instrumental to WP6 (Pharmacology) of the FACT project.

In the absence of feedback from Global Health EDCTP3 before the proposal deadline, this document serves as a provisional letter of endorsement:

UHAM commits to contribute in-kind (IKOP) support. This support includes personnel cost. This contribution strengthens the ability of the JU to deliver on its objectives by ensuring seamless carry-out tasks in WP6.

UHAM contribution falls in two project areas of the FACT project: Work package 6 coordination (lead), performance of bioanalysis and pharmacometric modelling and simulations to develop a dosing rationale for the FACT regimen. It covers provision of additional manpower for the FACT project.

We estimate the total value of this contribution to be EUR 358,723.58 for the 60-month duration of the project as in-kind contribution, all devoted to personnel cost in WP6.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.

2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,



Prof. Dr. Sebastian Wicha
Head of the research group Clinical Pharmacy